Valuation : AbbVie Inc.

Market Cap 443B 7,487B 381B 359B 327B 612B 42,179B 614B 4,247B 1,642B 21,498B 1,664B 1,628B 68,047B P/E 2026 *
32.1x
P/E 2027 * 23.9x
Enterprise Value 504B 8,509B 433B 408B 372B 695B 47,934B 698B 4,826B 1,866B 24,431B 1,891B 1,851B 77,330B EV / Sales 2026 *
7.46x
EV / Sales 2027 * 6.73x
Free-Float
95.71%
Yield 2026 *
2.73%
Yield 2027 * 2.87%
09-09 AbbVie Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 10:15 AM
09-08 BofA Securities Adjusts Price Target on AbbVie to $282 From $276 MT
09-03 AbbVie Announces Positive Topline Results From The Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma CI
09-03 AbbVie Inc. completed the acquisition of Apogee Therapeutics, Inc. from Fairmount Healthcare Fund II L.P managed by Fairmount Funds Management LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P managed by Venrock Management, LLC and other shareholders. CI
09-03 AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints MT
09-03 AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study DJ
09-03 AbbVie's blood cancer therapy lowers disease progression, death risk in trial RE
09-03 AbbVie's blood cancer drug meets late-stage trial goals RE
09-03 AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics MT
09-01 Global pharma companies that have publicly announced Trump drug pricing agreements RE
09-01 AbbVie Inc Receives Determination From Food And Drug Administration Regarding NAMENDA (Memantine Hydrochloride) Tablets 5 Mg And 10 Mg CI
08-27 AbbVie Seeks EU Approval for Subcutaneous Skyrizi Induction in Crohn's Disease MT
08-27 AbbVie Seeks European Regulatory Nod to Use Skyrizi as Subcutaneous Induction for Crohn's Disease Treatment MT
1 day-4.01%
1 week-3.10%
Current month-3.10%
1 month+1.55%
3 months+8.81%
6 months+2.86%
Current year+3.42%
1 week 4,250
Extreme 4250
4,250
1 month 4,250
Extreme 4250
4,515
Current year 3,420
Extreme 3420
4,635
1 year 3,420
Extreme 3420
4,635
3 years 2,375
Extreme 2375
4,635
5 years 2,115.61
Extreme 2115.61
4,635
10 years 1,062.02
Extreme 1062.02
4,635
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Change 5-day change 1-year change 3-year change Capi.($)
-4.01%-3.10% - - 440B
+0.03%-3.09%+52.20%+91.69% 1,002B
-0.76%-1.52%+49.94%+66.34% 649B
+0.86%-3.49%+19.60%+68.37% 440B
-0.80%+0.06%+28.73%+35.45% 346B
-0.13%-14.74%+9.13%+26.71% 263B
-1.90%-2.61%-2.67%+7.41% 250B
-0.48%-10.69%+39.64%+50.82% 213B
-1.06%-1.70%-16.73%-57.36% 201B
-0.68%-2.85%+25.69%+91.64% 182B
Average -0.75%-2.06%+22.84%+42.34% 393.74B
Weighted average by Cap. -0.53%-2.39%+32.37%+57.01%

Financials

2026 *2027 *
Net sales 67.58B 1,141B 58.08B 54.73B 49.88B 93.28B 6,429B 93.63B 647B 250B 3,277B 254B 248B 10,372B 73.52B 1,242B 63.18B 59.54B 54.26B 101B 6,994B 102B 704B 272B 3,565B 276B 270B 11,283B
Net income 13.86B 234B 11.91B 11.23B 10.23B 19.13B 1,319B 19.2B 133B 51.34B 672B 52.03B 50.91B 2,127B 18.91B 319B 16.25B 15.32B 13.96B 26.11B 1,799B 26.2B 181B 70.05B 917B 71B 69.47B 2,903B
Net Debt 60.49B 1,021B 51.99B 48.99B 44.64B 83.49B 5,754B 83.8B 579B 224B 2,933B 227B 222B 9,283B 51.66B 872B 44.4B 41.84B 38.13B 71.3B 4,915B 71.57B 495B 191B 2,505B 194B 190B 7,928B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
08/09/26 MX$4,250.00 -4.01% 17
02/09/26 MX$4,427.61 +0.95% 4,693
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
248.78USD
Average target price
276.79USD
Spread / Average Target
+11.26%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!